background
febril
neutropenia
common
complic
children
undergo
chemotherapi
malign
microbi
agent
identifi
fever
episod
correspond
mostli
bacteri
find
object
investig
viral
infect
possibl
etiolog
agent
episod
febril
neutropenia
studi
design
nasopharyng
aspir
npa
patient
present
neutropen
fever
two
pediatr
oncolog
ward
sweden
australia
analyz
convent
virusdiagnost
approach
rtpcr
coupl
blood
sampl
analyz
detect
cmv
ebv
adenoviru
erythroviru
bacteri
blood
cultur
perform
routin
result
convent
virusdiagnost
approach
coupl
routin
perform
bacteri
analyz
reveal
infecti
agent
compar
use
pcr
ad
pcr
viral
pathogen
detect
npa
blood
sampl
collect
half
patient
bacteremia
respiratori
tract
virus
codetect
conclus
respiratori
virus
frequent
detect
npa
suggest
signific
role
viral
infect
children
present
neutropen
fever
mean
find
need
evalu
potenti
individu
infect
treatment
reduc
extens
use
antibiot
immunocompromis
children
neutropenia
infect
major
caus
morbid
mortal
children
experienc
neutropenia
secondari
chemotherapi
identif
neutropen
episod
use
promptli
administ
empir
broad
spectrum
antibiot
reduc
mortal
consequ
patient
group
high
antibiot
pressur
risk
select
colon
fungi
multiresist
bacteria
viral
infect
especi
respiratori
viral
pathogen
account
signific
morbid
children
gener
therefor
like
overrepresent
viral
infect
also
present
febril
episod
children
neutropenia
howev
diagnost
therapeut
option
scarc
motiv
extens
investig
caus
agent
detect
case
etiolog
search
microbiolog
agent
febril
neutropen
episod
requir
strengthen
clinic
manag
group
patient
object
studi
investig
virus
role
possibl
etiolog
agent
children
cancer
treatment
present
neutropen
fever
studi
conduct
pediatr
oncolog
unit
children
hospit
westmead
sydney
australia
astrid
lindgren
children
hospit
karolinska
univers
hospit
stockholm
sweden
respect
studi
period
year
start
januari
children
neutropen
febril
episod
defin
axillari
temperatur
c
two
occas
min
apart
c
one
occas
absolut
neutrophil
count
cellsmm
invit
particip
studi
inform
consent
obtain
pair
nasopharyng
aspir
npa
peripher
blood
sampl
collect
blood
cultur
obtain
routin
laboratori
assess
addit
bacteria
sampl
perform
guid
symptom
result
blood
cultur
present
studi
clinic
data
extract
medic
journal
convent
viral
detect
immunofluores
viral
cultur
perform
studi
site
respect
use
local
accredit
protocol
detect
viral
nucleic
acid
npa
blood
sampl
batch
analyz
karolinska
univers
hospit
use
local
accredit
method
total
nucleic
acid
extract
npa
analyz
use
realtim
semiquantit
pcr
target
panel
respiratori
virus
rsv
flu
b
piv
ev
adv
hrv
bocaviru
hbov
metapneumoviru
hmpv
coronavirus
cov
kiwu
polyomavirus
kipyvwupyv
quantit
realtim
pcr
also
use
dna
detect
cmv
total
nucleotid
extract
peripher
blood
adv
total
nucleotid
extract
plasma
ebv
human
erythroviru
total
nucleotid
extract
serum
npa
bacteri
analysi
perform
local
clinic
microbiolog
laboratori
accredit
method
sampl
per
normal
clinic
routin
result
expand
viral
analyz
avail
clinician
real
time
group
comparison
perform
kruskalw
test
clinic
paramet
graph
pad
softwar
total
patient
includ
studi
exclud
due
incomplet
sampl
n
lack
materi
pcr
analyz
n
henc
sampl
process
episod
stockholm
sydney
respect
obtain
individu
femal
median
age
year
rang
year
sixtynin
percent
episod
deriv
patient
undergo
treatment
hematolog
malign
solid
tumor
median
eight
episod
includ
per
month
rang
appar
season
convent
assess
viral
cultur
npa
sampl
reveal
episod
presenc
one
viral
pathogen
six
hrv
three
cmv
one
identifi
sydney
studi
site
addit
bacteremia
identifi
episod
total
convent
virusdiagnost
approach
infecti
agent
identifi
episod
febril
neutropenia
npa
sampl
evalu
use
realtim
pcr
target
virus
detect
cultur
except
cmv
addit
agent
normal
detect
cultur
hbov
hmpv
cov
kipyv
wupyvv
addit
npa
peripher
blood
sampl
taken
enrol
assess
cmv
adv
ebv
erythroviru
find
shown
tabl
one
viral
pathogen
identifi
episod
overallin
npa
sampl
peripher
blood
sampl
total
infecti
agent
identifi
episod
febril
neutropenia
use
diagnost
approach
includ
pcrbase
viru
detect
differ
frequenc
detect
pathogen
patient
hematolog
malign
one
solid
tumor
twentytwo
episod
least
one
viru
detect
capac
detect
overlap
convent
method
realtim
pcr
tabl
convent
techniqu
could
detect
viru
seven
episod
median
threshold
cycl
ct
rang
sampl
viru
detect
pcr
median
ct
rang
eight
individu
npa
sampl
repeatedli
separ
neutropen
fever
episod
assess
whether
viru
clear
persist
realtim
pcr
individu
five
demonstr
clearanc
median
week
rang
week
three
viru
persist
detect
two
rhinoviru
one
median
week
rang
week
differ
clinic
pictur
patient
differ
detect
pathogen
group
detect
pathogen
sought
tabl
statist
signific
record
longer
hospit
group
bacteremia
copres
viru
npa
group
bacteremia
compar
group
dissemin
viral
infect
microbi
agent
detect
one
case
fatal
outcom
record
group
bacteria
detect
blood
report
show
pcrbase
viral
diagnost
greatli
increas
detect
infecti
agent
febril
episod
neutropenia
children
addit
assay
detect
recent
describ
virus
virus
difficult
detect
convent
method
also
contribut
higher
detect
rate
also
note
use
extend
viral
cultur
routin
includ
detect
hrv
one
studi
laboratori
clearli
contribut
higher
yield
posit
find
previous
report
studi
aim
detect
broad
rang
virus
children
neutropen
fever
pediatr
oncolog
set
use
pcrtechniqu
christensen
et
al
report
prospect
studi
popul
children
cancer
treatment
detect
viru
oral
wash
nasal
swab
note
sever
infecti
complic
patient
convers
koskenvuo
et
al
found
evid
viral
infect
nasal
swab
children
leukemia
signific
associ
neutropenia
present
studi
focus
patient
present
neutropen
fever
could
confirm
koskenvuo
high
detect
rate
respiratori
tract
virus
also
hrv
common
detect
pathogen
differ
sampl
procedur
probabl
explain
discrep
present
studi
studi
christensen
et
al
copres
respiratori
viru
detect
half
episod
bacteremia
also
correspond
found
group
children
acut
leukemia
interestingli
differ
clinic
pictur
paramet
detect
materi
except
longer
hospit
group
patient
bacteremia
copres
respiratori
viru
bacteremia
alon
compar
group
dissemin
viral
infect
microbi
agent
detect
tabl
whether
reflect
sever
clinic
pictur
group
codetect
bacteremia
respiratori
viru
bacteremia
alon
milder
cours
group
patient
dissemin
viral
infect
agent
detect
could
rule
studi
util
pcrtechniqu
viral
detect
thu
advantag
increas
sensit
compar
viral
cultur
antigen
detect
howev
clear
whether
detect
viral
nucleic
acid
actual
repres
direct
caus
agent
neutropen
fever
posit
pcr
result
could
also
repres
subclin
infect
postinfect
viral
shed
intracellular
nonrepl
viral
nucleic
acid
remnant
howev
recent
prospect
studi
repeat
sampl
infant
show
viru
detect
consecut
sampl
npa
week
case
rare
viru
genotyp
prolong
viral
shed
rsv
influenza
report
children
cancer
patient
studi
koskenvuo
et
al
whose
followup
sampl
taken
day
first
one
neg
wherea
four
patient
remain
virusposit
present
studi
eight
individu
npa
sampl
repeatedli
separ
neutropen
fever
episod
five
demonstr
clearanc
whether
three
patient
remain
viru
posit
due
persist
infect
new
infect
differ
genotyp
could
rule
sinc
perform
sequenc
patient
also
sampl
shorter
interv
may
receiv
stronger
immunosuppress
repres
sever
underli
diseas
howev
indic
koskenvuo
et
al
present
studi
major
virus
detect
eventu
clear
support
fact
viru
correspond
acut
infect
order
decreas
usag
broad
spectrum
antibiot
role
detect
virus
caus
agent
need
clarifi
futur
studi
followup
sampl
also
inclus
control
would
also
help
studi
mean
differ
viral
load
correl
clinic
diseas
although
dissemin
cmv
ebv
adv
describ
major
caus
morbid
mortal
children
undergo
hematopoiet
stemcel
transplant
hsct
thoroughli
assess
children
neutropenia
studi
virus
present
febril
episod
thu
signific
caus
morbid
set
like
due
less
profound
immunosuppress
major
children
compar
patient
undergo
hsct
case
erythroviru
infect
may
also
reflect
need
analyz
bone
marrowsampl
find
persist
infect
peripher
viremia
low
absent
sever
studi
tri
identifi
risk
factor
singl
patient
highest
risk
life
threaten
infect
need
hospit
care
broad
spectrum
antibiot
patient
lower
risk
therebi
suitabl
less
broad
even
ambulatori
treatment
ad
pcrbase
viral
diagnost
microbi
investig
children
neutropen
fever
could
greatli
enhanc
diagnost
sensit
studi
need
address
causal
viral
load
associ
clinic
diseas
group
patient
futur
applic
agil
broad
microbi
diagnost
may
howev
provid
decreas
use
antibiot
individu
infectionmanag
group
patient
author
declar
conflict
interest
